QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.007625v1 34/4/534    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marechal, J.-D. Articles by Sutcliffe, M. J. Search for Related Content PubMed PubMed Citation Articles by Marechal, J.-D. Articles by Sutcliffe, M. J.

IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER

Manchester Interdisciplinary Biocentre, School of Chemical Engineering and Analytical Science, University of Manchester, Manchester, United Kingdom (J.-D.M., M.J.S.); Biomedical Research Centre, University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom (J.Y., S.B., I.K., E.M.R., C.R.W., M.J.I.P.); and Department of Biochemistry, University of Leicester, Leicester, United Kingdom (G.C.K.R.)

Cytochrome P450 3A4 (CYP3A4) is the major enzyme responsible for phase I drug metabolism of many anticancer agents. It is also a major route for metabolism of many drugs used by patients to treat the symptoms caused by cancer and its treatment as well as their other illnesses, for example, cardiovascular disease. To assess the ability to inhibit CYP3A4 of drugs most commonly used by our patients during cancer therapy, we have made in silico predictions based on the crystal structures of CYP3A4. From this set of 33 common comedicated drugs, 10 were predicted to be inhibitors of CYP3A4, with the antidiarrheal drug loperamide predicted to be the most potent. There was significant correlation (r² = 0.75–0.66) between predicted affinity and our measured IC₅₀ values, and loperamide was confirmed as a potent inhibitor (IC₅₀ of 0.050 ± 0.006 µM). Active site docking studies predicted an orientation of loperamide consistent with formation of the major (N-demethylated) metabolite, where it interacts with the phenylalanine cluster and Arg-212 and Glu-374; experimental evidence for the latter interaction comes from the 12-fold increase in K_M for loperamide observed for the Glu-374-Gln mutant. The commonly prescribed drugs loperamide, amitriptyline, diltiazem, domperidone, lansoprazole, omeprazole, and simvastatin were identified by our in silico and in vitro screens as relatively potent inhibitors of CYP3A4 that have the potential to interact with cytotoxic agents to cause adverse effects, highlighting the likelihood of drug-drug interactions affecting chemotherapy treatment.

This article has been cited by other articles:

				R. Z. Cer, U. Mudunuri, R. Stephens, and F. J. Lebeda IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding Nucleic Acids Res., July 1, 2009; 37(suppl_2): W441 - W445. [Abstract] [Full Text] [PDF]

				S. C. Armstrong, G. H. Wynn, and N. B. Sandson Pharmacokinetic Drug Interactions of Synthetic Opiate Analgesics Psychosomatics, March 1, 2009; 50(2): 169 - 176. [Abstract] [Full Text] [PDF]

				H. Sun, C. Moore, P. M. Dansette, S. Kumar, J. R. Halpert, and G. S. Yost Dehydrogenation of the Indoline-Containing Drug 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (Indapamide) by CYP3A4: Correlation with in Silico Predictions Drug Metab. Dispos., March 1, 2009; 37(3): 672 - 684. [Abstract] [Full Text] [PDF]

				Y. Kapelyukh, M. J. I. Paine, J.-D. Marechal, M. J. Sutcliffe, C. R. Wolf, and G. C. K. Roberts Multiple Substrate Binding by Cytochrome P450 3A4: Estimation of the Number of Bound Substrate Molecules Drug Metab. Dispos., October 1, 2008; 36(10): 2136 - 2144. [Abstract] [Full Text] [PDF]

				K. Yasuda, A. Ranade, R. Venkataramanan, S. Strom, J. Chupka, S. Ekins, E. Schuetz, and K. Bachmann A Comprehensive in Vitro and in Silico Analysis of Antibiotics That Activate Pregnane X Receptor and Induce CYP3A4 in Liver and Intestine Drug Metab. Dispos., August 1, 2008; 36(8): 1689 - 1697. [Abstract] [Full Text] [PDF]

				S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al. The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709. [Abstract] [Full Text] [PDF]

				J. Yu, M. J. I. Paine, J.-D. Marechal, C. A. Kemp, C. J. Ward, S. Brown, M. J. Sutcliffe, G. C. K. Roberts, E. M. Rankin, and C. R. Wolf IN SILICO PREDICTION OF DRUG BINDING TO CYP2D6: IDENTIFICATION OF A NEW METABOLITE OF METOCLOPRAMIDE Drug Metab. Dispos., August 1, 2006; 34(8): 1386 - 1392. [Abstract] [Full Text] [PDF]